Clinical Advisors

SYN-004 (Ribaxamase) Advisors

Professor Mark Wilcox, MD, FRCPath

C. difficile Clinical Advisory Board (Chair)

Professor Mark Wilcox M.D., FRCPath, is a Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, as well as the lead on Clostridioides difficile for Public Health England in the UK. Dr. Wilcox was formerly the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at LTHT. He is deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection Committee and is a member of the HPA’s Program Board on Healthcare Associated Infection & Antimicrobial Resistance. Dr. Wilcox has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents.

Curtis Donskey, MD

C. difficile Clinical Advisory Board

Dr. Curtis Donskey is Associate Professor of Medicine at Case Western Reserve University School of Medicine, as well as Chairman of the Infection Control Committee at the Louis Stokes Cleveland Veterans’ Affairs Medical Center. Dr. Donskey’s expertise and research focus includes the epidemiology and transmission of C. difficile infections in the elderly and in nursing home populations, as well as the infection control issues of antibiotic use. Dr. Donskey has moderated a number of national conferences on the epidemiology of C. difficile.

CiarĂ¡n P. Kelly, MD

C. difficile Clinical Advisory Board

Dr. Ciarán Kelly is Professor of Medicine at Harvard Medical School, as well as Director of Gastroenterology Fellowship Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center in Boston, MA. Dr. Kelly has longstanding clinical and research interests into the causes, diagnosis and treatment of Clostridioides difficile infection, and he leads NIH-funded research on C. difficile colitis. Dr. Kelly has authored numerous clinical and basic research book chapters, invited reviews, and more than 100 peer-reviewed publications appearing in such journals as Infection & Immunity, American Journal of Physiology, Gastroenterology, Journal of Biological Chemistry, Journal of Clinical Investigation, The Lancet and New England Journal of Medicine.

Thomas Louie, MD

C. difficile Clinical Advisory Board

Dr. Thomas Louie is Professor of Medicine in the Department of Medicine and Microbiology-Immunology & Infectious Diseases at the University of Calgary in Alberta, Canada. Dr. Louie also serves as Infection Prevention & Control officer at Alberta Health Services and was the Medical Director of the Infection Prevention and Control Program in the Calgary Health Region 1998-2013. He is involved in clinical trials of new antimicrobial agents primarily for the treatment of C. difficile infection. Dr. Louie’s research interests include the ecology of hospital-acquired infections in patients receiving antibiotics and studies on the role of the gut microflora and its replacement by fecal transplantation for the treatment of recurrent C. difficile infection, and possible roles for the prevention of other nosocomial infections.

Additional Advisors

Richard Hodin, MD

Intestinal Alkaline Phosphatase Clinical Advisory Board

Dr. Hodin received his medical degree at Tulane University and then came to Boston in 1984 for his post-graduate surgical training. In 2001 he moved from the Beth Israel Deaconess Medical Center to the Massachusetts General Hospital (MGH) and in 2005 was promoted to full Professor of Surgery at Harvard Medical School. Dr. Hodin's clinical areas of expertise are in colorectal and endocrine surgery. He serves as Surgical Director of the MGH Crohns and Colitis Center and has a high-volume surgical practice involving the care of patients with Crohns disease and Ulcerative Colitis. His particular areas of interest are in minimally-invasive approaches to the treatment of Crohns patients, as well as the ileo-anal J-pouch operation for patients with colitis and Familial Adenomatous Polyposis. Dr. Hodin also serves as the Chief of the MGH Endocrine Surgery Unit, the highest volume center in the country focused on surgery of the thyroid, parathyroid, and adrenal glands. His particular areas of clinical expertise are in the treatment of advanced thyroid cancer, minimally-invasive parathyroidectomy, and the surgical treatment of adrenal tumors. In addition to his clinical practice, Dr. Hodin runs a highly productive research program focused on gut mucosal defense. His research laboratory has enjoyed extensive funding from the NIH and other sources since 1993 and has made important advances to our understanding of how humans interact with the bacteria within our intestine. His research group has identified several novel treatment strategies designed to prevent and/or treat a variety of intestinal diseases.